| تعداد نشریات | 282 |
| تعداد نشریات سازمان | 80 |
| تعداد شماره‌ها | 3,272 |
| تعداد مقالات | 36,149 |
| تعداد مشاهده مقاله | 55,713,307 |
| تعداد دریافت فایل اصل مقاله | 94,492,177 |
Comparison of S2 Subunits of the Spike (S) Glycoprotein From Different Strains of SARS-Cov-2 (COVID-19), Aiming to Understand the S2 Role in Virus Transfection Which May Help Its Harness | ||
| Archives of Razi Institute | ||
| مقاله 10، دوره 81، شماره 1، فروردین و اردیبهشت 2026، صفحه 73-88 اصل مقاله (3.34 M) | ||
| نوع مقاله: Original Articles | ||
| شناسه دیجیتال (DOI): 10.66224/ARI.81.1.3422 | ||
| نویسندگان | ||
| Meisam Akrami1؛ Khosrow Aghaiypour Kolyani* 2؛ Maryam Tajabadi Ebrahimi1؛ Ashraf Mohammadi3؛ Nakisa Zarrabi Ahrabi1 | ||
| 1Department of Biology, C.T.C., Islamic Azad University, Tehran, Iran. | ||
| 2Department of Biotechnology, Behesht Aein Laboratory Complex (MABA), Tehran, Iran. & Department of Genomics and Genetic Engineering, Razi Vaccine and Serum Research Institute (RVSRI), Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran. | ||
| 3Department of Human Viral Vaccine, Razi Vaccine and Serum Research Institute (RVSRI), Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran. | ||
| چکیده | ||
| Introduction: In late 2019, an acute respiratory disease known as SARS-CoV-2 (COVID-19), caused by a novel coronavirus, emerged in Wuhan, China. This disease spread rapidly across China and globally. Many countries were compelled to develop and manufacture vaccines, antigens, diagnostic kits, and antiviral medications to mitigate mortality rates. Severe acute respiratory syndrome coronavirus2 (SARS-CoV2 or COVID-19) uses its spike (S) protein to enable the virus to enter host cells. The viral entry process is linked to the cleavage of the spike (S) protein at the S1| S2 site. This cleavage can take place either at the plasma membrane of the host cell (known as the early pathway) or within the endosomal membrane (referred to as the late pathway), which is determined by the type of host cell involved. Previous research has identified a unique insertion in the S2 region of COVID-19, which may enhance the virus’s ability to target cells that express the appropriate proteases and receptors. Materials & Methods: 3D models of the SARS-CoV and SARS-CoV2 (or COVID-19) spike-proteins (S-protein) were constructed, analyzed, and evaluated using the SARS-CoV spike-structure (PDB No.5X58) as a reference. The structure of CoVs models was reviewed using the online Cn3D V4.3.1 software. Additionally, CoVs sequences were analyzed utilizing the PiTou V3.0.2 software. Results: Bioinformatics simulation results indicated that the majority of structural mutations enhancing the efficiency and activity of the S2 subunit were located at the cleavage site (CVs) within the C-terminal region spanning from 654 to 691. Utilizing bioinformatics tools, an analysis of mutations was conducted within the S2 subunit at the excision site and C-terminal region in related CoVs. Additionally, it provided insights into the origin of mutations such as furin and CVs in COVID-19, and compared them with other CoVs. Conclusion: Most of the mutations that increase the aggressiveness of the S2 subunit were observed in the S2 C-terminal and CVs. Research has shown that furin and some other proteases are involved in processing these mutations. Among these, the transmembrane serine protease 2 (TMPRSS2) is crucial in enabling viral entry through the early pathway. | ||
| کلیدواژه‌ها | ||
| Human coronavirus؛ S2 spike protein؛ Recombinant vaccine؛ SARS-CoV2؛ Bioinformatics analysis | ||
|
سایر فایل های مرتبط با مقاله
|
||
| مراجع | ||
|
Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes CO, Finkin S, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature. 2021; 592(7855):616-22. [DOI:10.1038/s41586-021-03324-6] [PMID]
Yao Z, Zhang L, Duan Y, Tang X, Lu J. Molecular insights into the adaptive evolution of SARS-CoV-2 spike protein. J Infect. 2024; 88(3):106121. [DOI:10.1016/j.jinf.2024.106121] [PMID]
Coutard B, Valle C, De Lamballerie X, Canard B, Seidah NG, Decroly E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 2020; 176:104742. [DOI:10.1016/j.antiviral.2020.104742][PMID]
Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S, et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 2020; 30(4):343-55. [DOI:10.1038/s41422-020-0305-x][PMID]
Zhang NN, Zhang RR, Zhang YF, Ji K, Xiong XC, Qin QS, et al. Rapid development of an updated mRNA vaccine against the SARS-CoV-2 Omicron variant. Cell Res. 2022; 32(4):401-3. [DOI:10.1038/s41422-022-00626-w][PMID]
Chen RE, Zhang X, Case JB, Winkler ES, Liu Y, VanBlargan LA, et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med. 2021; 27(4):717-26. [DOI:10.1038/s41591-021-01294-w][PMID]
Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483):1260-3. [DOI:10.1126/science.abb2507] [PMID]
No Author. DTU Health Tech. ProP 1.0 Server [Internet]. 2026 [Updated 23 Feb 2026]. Available from: [Link]
Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020; 367(6485):1444-8. [DOI:10.1126/science.abb2762] [PMID]
Cai Y, Zhang J, Xiao T, Peng H, Sterling SM, Walsh Jr RM, et al. Distinct conformational states of SARS-CoV-2 spike protein. Science. 2020; 369(6511):1586-92. [DOI:10.1126/science.abd4251] [PMID]
Graham RL, Donaldson EF, Baric RS. A decade after SARS: strategies for controlling emerging coronaviruses. Nat Rev Microbiol. 2013; 11(12):836-48. [DOI:10.1038/nrmicro3143][PMID]
Gui M, Song W, Zhou H, Xu J, Chen S, Xiang Y, et al. Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding. Cell Res. 2017; 27(1):119-29. [DOI:10.1038/cr.2016.152] [PMID]
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. cell. 2020; 181(2):271-80. e8. [DOI:10.1016/j.cell.2020.02.052][PMID]
Huang Y, Yang C, Xu XF, Xu W, Liu SW. Structural and functional properties of SARS-CoV-2 spike protein: Potential antivirus drug development for COVID-19. Acta Pharmacol Sin. 2020; 41(9):1141-9. [DOI:10.1038/s41401-020-0485-4][PMID]
Noh JY, Jeong HW, Shin EC. SARS-CoV-2 mutations, vaccines, and immunity: Implication of variants of concern. Signal Transduct Target Ther. 2021; 6(1):203. [DOI:10.1038/s41392-021-00623-2][PMID]
Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020; 581(7807):221-4. [DOI:10.1038/s41586-020-2179-y][PMID]
Suryadevara N, Shrihari S, Gilchuk P, VanBlargan LA, Binshtein E, Zost SJ, et al. Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. Cell. 2021; 184(9):2316-31. e15. [DOI:10.1016/j.cell.2021.03.029][PMID]
Thorne LG, Bouhaddou M, Reuschl AK, Zuliani-Alvarez L, Polacco B, Pelin A, et al. Evolution of enhanced innate immune evasion by SARS-CoV-2. Nature. 2022; 602(7897):487-95. [DOI:10.1038/s41586-021-04352-y][PMID]
Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020; 181(2):281-92. e6. [DOI:10.1016/j.cell.2020.02.058][PMID]
Wang L, Zhou T, Zhang Y, Yang ES, Schramm CA, Shi W, et al. Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. Science. 2021; 373(6556):eabh1766. [PMID]
Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, et al. Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1. 7. Nature. 2021; 593(7857):130-5. [DOI:10.1038/s41586-021-03398-2][PMID]
Wrobel AG, Benton DJ, Xu P, Roustan C, Martin SR, Rosenthal PB, et al. SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin-cleavage effects. Nat Struct Mol Biol. 2020; 27(8):763-7. [DOI:10.1038/s41594-020-0468-7][PMID]
GenBank. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information [Internet]. 1982. Available from: [Link]
GISAID. Global initiative on sharing all influenza data [Internet]. 2026 [Updated 23 Feb 2026] Available from: [Link]
No Author. Molecular evolutionary genetics analysis [Internet]. 2026 [Updated 2026 Feb 23] Available from: [Link]
National Center for Biotechnology Information. NCBI’s 3D Structure Viewer [Internet]. 2026 [Updated 2026 Feb 23] Available from: [Link]
National Center for Biotechnology Information. Molecular Modeling Database [Internet]. 2026 [Updated 2026 Feb 23] Available from: [Link]
Zhang Q, Xiang R, Huo S, Zhou Y, Jiang S, Wang Q, et al. Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. Signal Transduct Target Ther. 2021; 6(1):233. [DOI:10.1038/s41392-021-00653-w][PMID]
Cameroni E, Bowen JE, Rosen LE, Saliba C, Zepeda SK, Culap K, et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature. 2022; 602(7898):664-70. [DOI:10.1038/s41586-021-04386-2][PMID]
Cele S, Gazy I, Jackson L, Hwa SH, Tegally H, Lustig G, et al. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature. 2021; 593(7857):142-6. [DOI:10.1038/s41586-021-03471-w] [PMID] | ||
|
آمار تعداد مشاهده مقاله: 1,194 تعداد دریافت فایل اصل مقاله: 630 |
||
